These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 37386663)
1. Empiric treatment of patients with sepsis and septic shock and place in therapy of cefiderocol: a systematic review and expert opinion statement. Cortegiani A; Ingoglia G; Ippolito M; Girardis M; Falcone M; Pea F; Pugliese F; Stefani S; Viale P; Giarratano A J Anesth Analg Crit Care; 2022 Jul; 2(1):34. PubMed ID: 37386663 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. Jorda A; Zeitlinger M Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355 [No Abstract] [Full Text] [Related]
10. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675 [TBL] [Abstract][Full Text] [Related]
11. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196 [TBL] [Abstract][Full Text] [Related]
12. Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence. Wang C; Yang D; Wang Y; Ni W Front Pharmacol; 2022; 13():896971. PubMed ID: 35496290 [TBL] [Abstract][Full Text] [Related]
13. Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Giacobbe DR; Ciacco E; Girmenia C; Pea F; Rossolini GM; Sotgiu G; Tascini C; Tumbarello M; Viale P; Bassetti M; Infect Drug Resist; 2020; 13():4697-4711. PubMed ID: 33402840 [TBL] [Abstract][Full Text] [Related]
17. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence. Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections. Drwiega EN; Griffith NC; Danziger LH Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):245-259. PubMed ID: 35594628 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]